Maysa Abu-Khalaf MBBS, MD

Associate Professor of Medicine (Medical Oncology) and of Obstetrics, Gynecology, and Reproductive Sciences

Departments & Organizations

Yale Medical Group

Cancer Center, Yale: Breast Cancer Program | Developmental Therapeutics

Medical Oncology

Obstetrics, Gynecology & Reproductive Sciences

Research Interests

Clinical trials evaluating novel agents for the treatment of breast, ovarian and endometrial cancers; PI3K-mTOR inhibitors; HER-2 targeted therapies; angiogenesis more...

Education

• M.B.B.S., Jordan University, 1995

Selected Publications

• Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20;27(21):3430-6. Epub 2009 May 26.
• Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung GG, DiGiovanna MP, Miller K, Higgins SA, Weidhaas J, Harris L, Tavassoli FA, Lannin DR. Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol. 2009 Mar;16(3):697-702. Epub 2009 Jan 9.

more...